Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults

被引：15

作者：

Ogawa, Yuji ^{[1
]}

Yoneda, Masato ^{[1
]}

Kobayashi, Takashi ^{[1
]}

Honda, Yasushi ^{[1
]}

Kessoku, Takaomi ^{[1
]}

Imajo, Kento ^{[1
]}

Saito, Satoru ^{[1
]}

Nakajima, Atsushi ^{[1
]}

机构：

[1] Yokohama City Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Yokohama, Kanagawa, Japan

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2019年 / 20卷 / 01期

基金：

日本学术振兴会;

关键词：

Non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; pharmacologic therapy; clinical trial; FATTY LIVER-DISEASE; PAN-CASPASE INHIBITOR; BILE-ACID TRANSPORTERS; HEPATOCELLULAR-CARCINOMA; AMERICAN ASSOCIATION; OBETICHOLIC ACID; THYROID-HORMONE; VITAMIN-E; PRACTICE GUIDELINES; INSULIN-RESISTANCE;

D O I：

10.1080/14656566.2018.1543403

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Multiple parallel factors are implicated in the pathogenesis and progression of non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH). Currently recommended therapies for NASH include vitamin E and pioglitazone, besides dietary and lifestyle changes. Areas covered: This review focuses on the clinical development of several emerging drugs for the treatment of NASH and the impact of these drugs on current treatment standards. Expert opinion: Four drug classes (FXR agonists, CCR2/CCR5 antagonists, ASK1 inhibitors, and PPAR alpha/delta agonists) have moved into phase 3 trials for their investigation as NASH treatments. Results from phase 2 trials of other therapeutic agents with other pharmacological actions are also expected. The importance of combinational therapies with synergistic benefits engaging different targets, is now understood. Furthermore, studies have determined that the Mediterranean diet is beneficial for patients with NAFLD, while the traditional Okinawan diet is also considered useful. In the future, it will be important to establish new biomarkers to assess NAFLD activity, furthermore non-invasive diagnostic methods will promote the development of new drugs for NASH.

引用

页码：69 / 82

页数：14

共 121 条

[1] The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].